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Introduction
Testing for HIV in the neonatal period has been routinely recommended for all HIV-exposed 
infants in the developed world for over two decades. In 2015, birth testing for certain asymptomatic 
HIV-exposed infants was included in the South African National Consolidated Guidelines for the 
first time.1 Questions remain concerning the optimal recommendations for and implementation 
of HIV testing in neonates to achieve improved outcomes for HIV-infected infants in South 
African and other low-resource settings.
Effect of evolving prevention of mother to child 
transmission interventions on 6-week HIV polymerase 
chain reaction diagnostic performance
The notion that a single HIV polymerase chain reaction (PCR) test performed at 6 weeks of age 
would detect virtually all in utero and intrapartum HIV-infected infants failed to recognise:
• the HIV-related mortality that occurs prior to testing at 6 weeks of age2,3,4
• the reduced sensitivity of HIV PCR tests as a consequence of the increase in the number 
and duration of drugs used for prevention of mother-to-child transmission of HIV (PMTCT) 
prophylaxis.
There is increasing evidence that both fixed dose combination (FDC) maternal PMTCT prophylaxis 
and daily dose nevirapine (NVP) infant prophylaxis (Option B or B+) contribute towards reduced 
detection of perinatal HIV infection at 6 weeks of age. The literature demonstrates that:
• a single perinatal dose of NVP reduced viral load to below the limit of detection in 38% and 
17% of in utero infected infants at 5 days and 2 weeks of age respectively.5,6 No HIV PCR sen-
sitivity data for 6-week-old HIV-exposed infants, tested at discontinuation of 6 weeks of daily 
dose NVP, are available.
• the probability of a positive HIV PCR at age 6 weeks in perinatally HIV-infected infants is 
decreased with multi-drug maternal and/or infant PMTCT prophylaxis7
• in non-breastfed infants, HIV DNA and RNA PCR sensitivity at 1 month of age for perinatally 
infected infants was 89%8
• in formula-fed infants who received 6 weeks of postpartum zidovudine (AZT), with or with-
out other antiretrovirals, 32% of intrapartum-infected infants tested HIV DNA PCR negative 
at 6 weeks of age but tested positive at 3 months of age9
• prophylaxis reduces HIV DNA concentrations at birth complicating early identification of 
infected infants for initiation of early treatment10
• there are case studies illustrating the challenges of ‘false negative’ and ‘indeterminate’ HIV 
PCR results in early infant diagnosis in the context of current PMTCT prophylaxis and calling 
for revised diagnostic guidelines.11,12
The 6-week test, conveniently scheduled at the same time as the 6-week expanded programme for 
immunisation (EPI) visit, is therefore too late and too early to detect all in utero and intrapartum 
HIV infections in the context of current PMTCT interventions. It is too late to diagnose infants 
who die prior to 6 weeks of age and to achieve early combination antiretroviral therapy (cART) 
initiation by 7.4 weeks of age as was done on the Children with HIV Early Antiretroviral Therapy 
(CHER) trial to reduce early morbidity and mortality.13 It is too early to diagnose in utero and 
intrapartum infections suppressed by daily dose NVP and/or maternal prophylaxis via the 
placenta and/or breastmilk.
Diagnostic performance of HIV PCR at birth
The HIV PCR sensitivity at birth for detecting perinatal HIV infections (viz. in utero and 
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and cannot detect intrapartum infection, namely an infection 
transmitted at the time of labour and delivery and essentially 
in the window period at birth. Prior to the implementation 
of PMTCT and the use of standardised HIV assays, Dunn 
et al.’s meta-analysis demonstrated that 38% of all perinatal 
infections were detectable at birth.14 With World Health 
Organization (WHO) Option A prophylaxis and a single 
dose of NVP at birth for infants, Lilian et al. demonstrated 
that 76% of all early HIV infections were detectable at 
birth.15 This increase was attributed to more sensitive viral 
detection assays and a proportional increase in in utero to 
intrapartum infections as a result of PMTCT prophylaxis 
targeting intrapartum infections during late pregnancy 
and delivery. As the majority of women deliver in health 
facilities in South Africa, identifying all HIV-infected women 
at delivery coupled with birth HIV PCR testing would yield 
three-quarters of all perinatal HIV infections with close to 
90% coverage.
With Option B or B+ including daily dose NVP for 6 weeks 
to the infant, the ratio of in utero to intrapartum infections 
detectable at birth and 6 weeks of age is not known but is 
likely to be similar to Option A.
When should birth and early 
neonatal HIV PCR be considered?
Because HIV testing of neonates is not performed unless a 
neonate is symptomatic, the HIV-related neonatal mortality 
rate in South Africa is unknown. In the presence of vertical 
transmission and without a birth diagnosis, it is neither 
possible to detect neonatal HIV infection nor to reduce 
HIV-related neonatal mortality by initiating antiretroviral 
therapy. Approximately 20% of infants known to be 
HIV-infected at birth in Johannesburg either died or were 
lost to follow-up by the time that 6-week HIV PCR testing 
was conducted.4
Modeling the ideal timing of HIV PCR tests in early infant 
diagnosis for South Africa,16 considering birth, 6-, 10- and 
14-week EPI visits, demonstrated that:
• when using 1 HIV PCR test, the same number of 
HIV-infected infants are identified when testing at birth 
or at 6 weeks of age
• when using 2 HIV PCR tests, the most HIV-infected 
 infants can be identified by testing at birth and 10 weeks 
of age.
Additional evidence for the assumptions made in the model 
would assist in refining the optimal timing of HIV PCR tests.
The 2014 South African National Consolidated Guidelines 
recommend targeted birth testing, namely HIV PCR testing 
of only those HIV-exposed neonates identified as being 
at high risk of HIV transmission.1 ‘High risk’ includes all 
premature (born before 37 weeks’ gestational age), low 
birth weight (LBW < 2500 g) or symptomatic HIV-exposed 
neonates and those born to women who were unbooked or 
received a late diagnosis of HIV (e.g. at delivery) or received 
< 4 weeks of antiretroviral PMTCT prophylaxis or had viral 
loads > 1000 copies per millilitre or were co-infected with 
tuberculosis during pregnancy. The Western Cape PMTCT 
guidelines also recommend targeted birth testing that 
include additional and slightly modified high-risk factors.17 
These high-risk factors predict vertical transmission but not 
necessarily in utero transmission, and therefore the birth HIV 
PCR test may be negative.
Universal birth testing of all HIV-exposed infants may be 
simpler to implement than targeted birth testing. The cost 
of performing two early HIV PCR tests, to detect in utero 
and intrapartum infections, on every HIV-exposed infant 
can be offset by following 2010 WHO guidelines to use HIV 
rapid tests (HRT) from 9 months of age.18 As the majority of 
HIV-exposed, uninfected infants demonstrate seroreversion 
by 9 months of age by testing HRT negative, only those 
with positive HRT would require HIV PCR tests.19 This 
approach reduces the number of HIV PCR tests required for 
symptomatic infants or those requiring testing post-cessation 
of breastfeeding.
Optimal response to a birth  
or early neonatal HIV PCR  
result that is positive
To avoid morbidity and mortality, all positive HIV PCR 
results require urgent action to (1) confirm the HIV-infected 
status on a second blood sample and (2) initiate cART. 
Healthcare facilities require good communication with the 
laboratory to access positive results within 2–7 days and 
systems for patient follow-up to see all HIV PCR-positive 
patients as soon as possible. As neonates usually return to 
their primary healthcare clinic and not the maternity unit for 
follow-up after birth, ensuring that birth HIV PCR test results 
reach patients will be pivotal to successful implementation 
of birth testing. Point of care (POC) HIV diagnosis 
would facilitate same-day identification of HIV-infected 
neonates.
The results of the second, confirmatory viral detection assay 
should not delay cART initiation but should be obtained 
as early as possible because, once cART is initiated, it 
becomes progressively more difficult to detect HIV either 
by HIV PCR or viral load testing. The availability of two 
different POC assays for detection of HIV would facilitate 
same-day identification and confirmation of HIV infection 
in neonates.
Further testing if birth or early 
neonatal HIV PCR test result 
is negative
If the birth HIV PCR test is negative, an HIV PCR test at 
10 weeks of age is recommended to detect as many cases 
of intrapartum infection as possible. If the HIV PCR test is 
repeated at 6 weeks of age, as per national guidelines,1 fewer 
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cases of intrapartum infection may be identified owing to 
the viral load lowering effect of the daily dose NVP infant 
prophylaxis. The 2014 National Consolidated Guidelines 
cater for this in high-risk infants only by recommending a 
third HIV PCR at 16 weeks of age where prolonged infant 
prophylaxis (e.g. daily dose NVP for 12 weeks) has been 
used.1 The probability that the sensitivity of diagnostic 
virological assays is affected by antiretroviral prophylaxis 
has prompted American guidelines to recommend an 
additional HIV PCR test be performed 2–4 weeks after 
combination antiretroviral infant prophylaxis has been 
discontinued if negative HIV PCR results were obtained 
during prophylaxis.20 As for all HIV-exposed and uninfected 
infants, HIV PCR testing is recommended whenever clinical 
features suggestive of HIV infection are present and 6 weeks 
after cessation of breastfeeding (if < 18 months old). If, at 
6 weeks after weaning, the child is ≥ 18 months old, a HRT 
or HIV enzyme-linked immunosorbent assay (ELISA) test 
should be performed instead of an HIV PCR test.
In an evolving PMTCT environment, ongoing monitoring 
is necessary to assess the impact of early diagnosis of HIV 
infection in neonates and to ensure that an evidence-based, 
effective diagnostic algorithm is deployed.
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